Apparatus and method for prediction hypertensive chronic kidney disease based on genome-metabolomics integration analysis

The genome-metabolite integrated analysis method identifies key genetic markers for predicting and managing hypertensive chronic kidney disease, addressing the lack of predictive tools and offering opportunities for targeted interventions and drug development.

KR103043980B1Active Publication Date: 2026-11-11SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020230006205
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-01-17
Filing Date
2023-01-16
Publication Date
2026-11-11
Estimated Expiration
2043-01-16

AI Technical Summary

Technical Problem

Current methods fail to effectively predict the onset and progression of hypertensive chronic kidney disease in the general Korean population, and there is a lack of comprehensive understanding of genetic and metabolic factors contributing to rapid declines in estimated glomerular filtration rate.

Method used

A genome-metabolite integrated analysis method that identifies single nucleotide polymorphisms, such as rs145083655 and rs183537972, associated with rapid eGFR decline, using linear regression models to analyze genomic and metabolite data, enabling prediction and diagnosis of chronic kidney disease.

Benefits of technology

This approach allows for the identification of significant biomarkers for chronic kidney disease, facilitating proactive prevention and potential drug development, reducing the socioeconomic burden and enabling personalized medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023005775553-PAT00002_ABST
    Figure 112023005775553-PAT00002_ABST
Patent Text Reader

Abstract

An apparatus and method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis are disclosed. A method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention may include: a step of collecting genomic information data of a plurality of subjects; a step of estimating the glomerular filtration rate slope of each of the plurality of subjects based on the genomic information data and selecting genomic information data in which the estimated glomerular filtration rate slope satisfies a preset slope condition; a step of performing an association analysis between metabolite concentration and allele score based on a linear regression model linked to the metabolite concentration and allele information of blood data using the selected genomic information data; and a step of deriving analysis information on single nucleotide polymorphisms significantly associated with a phenotype linked to a target disease based on the results of the association analysis.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to an apparatus and method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis. For example, the present invention relates to the discovery of single nucleotide polymorphisms associated with a rapid decrease in estimated glomerular filtration rates for predicting the onset and exacerbation of hypertensive chronic kidney disease in the general Korean population based on genome-metabolite integrated analysis, and methods for utilizing such polymorphisms. Background Technology

[0002] Chronic kidney disease (CKD) has increased rapidly over the past few decades, affecting up to 10% of adults worldwide, and rapid decline in renal function, such as a decrease in estimated glomerular filtration rate (eGFR), is considered a significant risk factor for end-stage renal disease (ESRD), cardiovascular events, and premature death.

[0003] In this regard, previous meta-analyses based on observational and randomized controlled trials (RCTs) have suggested that the estimated glomerular filtration rate slope can be considered a surrogate endpoint for ESRD in clinical trials based on the general population, and that treating patients early in the progression of CKD before the estimated glomerular filtration rate declines rapidly may be more beneficial than treatment provided for intractable progressive CKD, and that meta-analyses based on observational data have suggested that screening the general population for a rapid decline in eGFR can prevent CKD.

[0004] While diabetes and hypertension are representative risk factors for CKD, the risk of chronic kidney disease has not been fully explained. Furthermore, the heritability of estimated glomerular filtration rate has been estimated to be up to 36-75% in population-based studies, which motivated genome-wide association studies (GWAS) related to estimated glomerular filtration rate.

[0005] Furthermore, according to meta-analysis on Caucasians and whole-genome association analysis results regarding the decline in estimated glomerular filtration rate based on animal models, it can be seen that there are unique genetic variations associated with changes in estimated glomerular filtration rate in addition to those identified in one-time measurements. While previous studies have performed whole-genome association analysis on the rapid decline in defined eGFR in the general European population, this has not yet been investigated in whole-genome association analysis recommended for clinical use.

[0006] Meanwhile, in Asia, whole-genome association studies based on meta-analysis of cross-sectional estimated glomerular filtration rate have been performed, but whole-genome association studies on longitudinal changes in estimated glomerular filtration rate have not yet been conducted. Therefore, it is necessary to identify genetic variants by performing whole-genome association studies based on participants in the domestic general population who experienced a rapid decline in estimated glomerular filtration rate prior to the onset of chronic kidney disease.

[0007] Nevertheless, the identification of genetic variants alone may not be sufficient to understand the sharp decline in the estimated glomerular filtration rate gradient in the general population, and given that metabolites are the end products of biological pathways, an integrated study was recently conducted to evaluate the influence of genetic variation on phenotypes associated with metabolite enrichment.

[0008] Furthermore, mapping genetic associations at the multimolecular level through the integrated analysis of metabolites and genetic variants in genome-genome association can significantly improve the interpretation of human genetic variants and enhance the understanding of biological mechanisms and networks. In particular, comprehensive understanding of complex diseases such as chronic kidney disease is possible through in silico-based system integration analysis. Therefore, there is a need to develop biomarkers that can predict the onset and prognosis of chronic kidney disease in hypertensive patients—a high-risk group for the disease in the general Korean population—or serve as candidates for drug treatment. This can be achieved by identifying genetic variants (single nucleotide polymorphisms) associated with a very rapid decline in estimated glomerular filtration rate and evaluating the association between these single nucleotide polymorphisms and serum metabolite concentration via genome-metabolite integration. The problem to be solved

[0009] The present invention aims to solve the problems of the aforementioned conventional technology by providing a method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis linked to biomarkers that can predict the onset and prognosis of chronic kidney disease or serve as candidates for drug treatment in hypertensive patients, who are a high-risk group for developing chronic kidney disease.

[0010] However, the technical problems that the embodiments of the present invention aim to solve are not limited to the technical problems described above, and other technical problems may exist. means of solving the problem

[0011] As a technical means for achieving the above-mentioned technical task, a method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention may include: a step of collecting genomic information data of a plurality of subjects; a step of estimating the glomerular filtration rate gradient of each of the plurality of subjects based on the genomic information data and selecting genomic information data in which the estimated glomerular filtration rate gradient satisfies a preset gradient condition; a step of performing an association analysis between metabolite concentration and allele score based on a linear regression model linked to the metabolite concentration and allele information of blood data using the selected genomic information data; and a step of deriving analysis information on single nucleotide polymorphisms significantly associated with a phenotype linked to a target disease based on the results of the association analysis.

[0012] In addition, the above target disease may include hypertensive chronic kidney disease.

[0013] In addition, the above screening step can screen for genomic data of subjects in which the estimated glomerular filtration rate slope decreases rapidly above a preset threshold slope.

[0014] In addition, the single base polymorphism may include at least one of rs145083655 and rs183537972.

[0015] In addition, a method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention may include the step of generating diagnostic information for the target disease of a subject using the analysis information.

[0016] In addition, the step of generating the diagnostic information may derive the diagnostic information associated with the subject's hypertensive chronic kidney disease based on information regarding an increase in blood creatinine concentration according to an effective allele of a single nucleotide polymorphism comprising at least one of rs145083655 and rs183537972.

[0017] Meanwhile, a device for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention may include a collection unit that collects genomic information data of a plurality of subjects, estimates the glomerular filtration rate slope of each of the plurality of subjects based on the genomic information data, and selects genomic information data in which the estimated glomerular filtration rate slope satisfies a preset slope condition; and a statistical analysis unit that performs an association analysis between metabolite concentration and allele score based on a linear regression model linked to the metabolite concentration and allele information of blood data using the selected genomic information data, and derives analysis information on single nucleotide polymorphisms significantly associated with a phenotype linked to a target disease based on the results of the association analysis.

[0018] In addition, a genome-metabolite integrated analysis-based hypertensive chronic kidney disease analysis device according to one embodiment of the present invention may include a diagnostic information generation unit that generates diagnostic information regarding the target disease of a subject using the analysis information.

[0019] Meanwhile, regarding a composition for detecting a single nucleotide polymorphism (SNP) marker to predict the occurrence and exacerbation of hypertensive chronic kidney disease according to one embodiment of the present invention, the single nucleotide polymorphism (SNP) marker may be one or more selected from the group consisting of rs145083655 and rs183537972.

[0020] Meanwhile, regarding a kit for diagnosing the prediction of occurrence and exacerbation of hypertensive chronic kidney disease using a single nucleotide polymorphism (SNP) marker according to one embodiment of the present invention, the single nucleotide polymorphism (SNP) marker may be one or more selected from the group consisting of rs145083655 and rs183537972.

[0021] The means for solving the problem described above are merely exemplary and should not be interpreted as intended to limit the present invention. In addition to the exemplary embodiments described above, additional embodiments may exist in the drawings and the detailed description of the invention. Effects of the invention

[0022] According to the aforementioned means for solving the problem of the present invention, a method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis linked to biomarkers that can predict the occurrence and prognosis of chronic kidney disease or serve as candidates for drug treatment in hypertensive patients who are at high risk of developing chronic kidney disease can be provided.

[0023] According to the aforementioned means for solving the problem of the present institution, for the proactive prevention of hypertensive chronic kidney disease, significant biomarkers can be identified regarding the occurrence of chronic kidney disease and the pre-stage of chronic kidney disease in the general population.

[0024] According to the aforementioned means for solving the problem of the present institution, verification can be performed through whole-genome association analysis not only on hypertension patients in the general population but also on the domestic population of patients with chronic kidney disease.

[0025] According to the aforementioned means for solving the problem of the present invention, by providing opportunities for new drug development based on drug targets for specific genes, there is a possibility of intervening not only in the onset of hypertensive chronic kidney disease but also in its progression.

[0026] According to the means for solving the problem of the present invention described above, genetic influence on metabolite concentration may ultimately have clinical significance due to the extensive influence of renal function on circulating metabolites and possible functional roles.

[0027] According to the aforementioned means for solving the problem of the present invention, by estimating the influence of genetic variations on metabolites within circulating biological metabolic mechanisms, insights into prevention and intervention can be provided through continuous monitoring of hypertensive patients at high risk of progression of chronic kidney disease.

[0028] However, the effects obtainable from this invention are not limited to those described above, and other effects may exist. Brief explanation of the drawing

[0029] FIG. 1 is a schematic diagram of a genome-metabolite integrated analysis-based hypertensive chronic kidney disease analysis device according to one embodiment of the present invention. Figure 2 shows the Manhattan plot and Q-Q plot of the genome-wide association analysis for the rapid decrease in eGFR in hypertensive patients from the Korean Chip Consortium (Discovery dataset). Figure 3 is a diagram showing the genomic characteristics of rs183537972 in 7q31.32. Figure 4 is a diagram showing the association between serum creatinine concentrations between rs183537972 located near the HYAL6P gene and rs145083655 located at the HYAL4 gene using a linear regression model of genome-metabolite integration analysis (GMIA). Figure 5 is a diagram showing verified single nucleotide polymorphisms associated with a rapid decrease in eGFR based on whole-genome association analysis. Figure 6 is a graph showing the fine-mapping results of rs183537972 and rs145083655 in the HYAL6P and HYAL4 genes of chromosome 7q31.32. Figure 7 is a diagram showing the results of a genome-metabolite analysis on the rapid decrease in eGFR. FIG. 8 is a flowchart of the operation of a method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention. Specific details for implementing the invention

[0030] Embodiments of the present invention are described below with reference to the attached drawings to enable those skilled in the art to easily implement the invention. However, the present invention may be embodied in various different forms and is not limited to the embodiments described herein. Furthermore, in order to clearly explain the present invention in the drawings, parts unrelated to the explanation have been omitted, and similar parts throughout the specification are denoted by similar reference numerals.

[0031] Throughout this specification, when a part is described as being "connected" to another part, this includes not only cases where they are "directly connected," but also cases where they are "electrically connected" or "indirectly connected" with other elements interposed between them.

[0032] Throughout the entire specification, when a component is described as being located "on," "on top," "on top," "under," "on bottom," or "on bottom" of another component, this includes not only cases where the component is in contact with the other component but also cases where another component exists between the two components.

[0033] Throughout this specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0034] This invention relates to a method for analyzing hypertensive chronic kidney disease based on integrated genome-metabolite analysis. For example, this invention concerns the discovery of single nucleotide polymorphisms associated with a rapid decrease in estimated glomerular filtration rates to predict the onset and exacerbation of hypertensive chronic kidney disease in the general Korean population based on integrated genome-metabolite analysis, and methods for utilizing these polymorphisms.

[0035] FIG. 1 is a schematic diagram of a genome-metabolite integrated analysis-based hypertensive chronic kidney disease analysis device according to one embodiment of the present invention.

[0036] Referring to FIG. 1, a genome-metabolite integrated analysis-based hypertensive chronic kidney disease analysis device (100) (hereinafter referred to as the 'analysis device (100)') according to one embodiment of the present invention may include a collection unit (110), a statistical analysis unit (120), and a diagnostic information generation unit (130).

[0037] The collection unit (110) can collect genomic information data of multiple subjects.

[0038] Additionally, the collection unit (110) can estimate the glomerular filtration rate gradient of each of a plurality of subjects based on the acquired genomic information data and select genomic information data in which the estimated glomerular filtration rate gradient satisfies a preset gradient condition. Specifically, the collection unit (110) can perform data preprocessing to select genomic information data of subjects in which the estimated glomerular filtration rate gradient decreases rapidly above a preset threshold gradient described below.

[0039] The statistical analysis unit (120) can perform an analysis of the association between metabolite concentration and allele score based on a linear regression model linked to the metabolite concentration and allele information of the blood data using selected genomic information data.

[0040] In addition, the statistical analysis unit (120) can derive analysis information on single nucleotide polymorphisms that are significantly associated with the phenotype associated with the target disease based on the results of the association analysis, as described in detail below.

[0041] The diagnostic information generation unit (130) can generate diagnostic information regarding the subject's target disease using the analysis information derived by the statistical analysis unit (120). In this regard, the target disease in the description of the embodiment of the present invention may include hypertensive chronic kidney disease.

[0042] More specifically, the diagnostic information generation unit (130) can derive diagnostic information associated with the subject's hypertensive chronic kidney disease based on information regarding an increase in blood creatinine concentration according to an effective allele of a single nucleotide polymorphism including at least one of the subject's rs145083655 and rs183537972.

[0043] Hereinafter, specific functions and operations of the analysis device (100) will be described with reference to FIGS. 2 to 7. FIGS. 2 to 7 are drawings for explaining a method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention.

[0044] According to one embodiment of the present invention, the analysis device (100) can perform an association analysis between the allele scores for single nucleotide polymorphisms that are significantly related to the phenotype in the results of whole-genome association analysis and the metabolite concentration and allele information of blood data based on a linear regression model.

[0045] In addition, the analysis device (100) can estimate the slope of the subject's glomerular filtration rate based on the results of the association analysis.

[0046] Additionally, the analysis device (100) can generate diagnostic information regarding the subject's chronic kidney disease based on the estimated glomerular filtration rate gradient.

[0047] Below, the correlation analysis or glomerular filtration rate slope estimation process performed by the analysis device (100) will be described in detail.

[0048] Single nucleotide polymorphism (SNP) refers to the expression of traits differently between individuals through genetic variations that show differences in the nucleotide sequences present in DNA between individuals. Among the causes of polymorphism, a single nucleotide polymorphism (SNP) is defined as the expression of different traits caused by variations in a single pair of nucleotide sequences that occur frequently in a population (usually with a frequency of 1% or more).

[0049] Genome-wide association study (GWAS) is an analytical method that identifies genetic variations associated with relevant phenotypes at all genomic locations.

[0050] MAF (Minor allele frequency) refers to the proportion of chromosomes containing a specific allele out of the total number of alleles. It is a term used to describe the second most frequent variation in a given population and primarily represents the proportion of chromosomes containing the effector allele.

[0051] An allele refers to a gene that forms a pair of homologous chromosomes and possesses different traits. It represents the DNA sequence of an allele, and the P-value signifies the probability that the test statistic is equal to or more extreme than the observed statistic, assuming the null hypothesis is true.

[0052] In addition, in the description of the embodiments of the present invention, "rs number" or "NCBI refSNP ID" refers to a unique number of SNPs registered in the SNP reference database of the National Center for Biotechnology Information (NCBI), and information about the corresponding SNP can be verified by accessing the database through this unique number. Therefore, when the rs number is specified in the present invention, information about the corresponding SNP, such as the chromosomal location where the corresponding SNP exists, genetic loci, and polymorphic sequences containing the SNP, can be easily verified.

[0053] Furthermore, fine-mapping refers to providing evidence that genomic regions are associated with phenotypes and assuming the existence of at least one causative variant to determine genetic variation, thereby identifying a credible set of potential causative variants for which probabilistic selection can be prioritized.

[0054] In addition, regarding the description of the embodiments of the present invention, Genome-Metabolomics Integrative Analysis (GMIA) is an analytical method that aims to elucidate the metabolic mechanisms underlying genetic variation by performing an association analysis between metabolite concentrations and allele scores for single nucleotide polymorphisms that are significantly associated with the phenotype in the results of whole-genome association analysis, based on a linear regression model. That is, according to the present invention, a linear regression model can be constructed between the metabolite concentrations of blood data calculated through metabolomics analysis and pre-calculated allele information.

[0055] Meanwhile, in the description of the embodiments of the present invention, the term "prediction of deterioration" may include evaluating and predicting in advance the damage and risks to the future kidney condition, such as damage to future kidney function, progression of reduced kidney function, risk of developing end-stage renal disease, risk of progression to chronic renal failure or end-stage renal failure, and risk of requiring renal replacement therapy such as dialysis or kidney transplantation.

[0056] In this regard, the estimated glomerular filtration rate (eGFR) refers to a value calculated according to the CKD-EPI formula (Chronic Kidney Disease Epidemiology Collaboration Equation). Since the glomerular filtration rate cannot be measured directly in the glomerulus, clinical practice mainly uses a method of estimating the glomerular filtration rate based on the plasma concentration of creatinine using the CKD-EPI formula (Chronic Kidney Disease Epidemiology Collaboration Equation), which takes into account factors such as age, gender, and weight; this can be referred to as the estimated glomerular filtration rate.

[0057] In addition, "glomerular filtration rate decline" or "estimated glomerular filtration rate decline" is generally an indicator that can predict the worsening of chronic kidney disease, so appropriate preventive and therapeutic measures are taken, such as determining the stage of kidney disease based on GFR, determining the dosage of nephrotoxic drugs, and assessing the course after renal replacement therapy.

[0058] The "glomerular filtration rate slope (GFR slope)" or "estimated glomerular filtration rate slope (eGFR slope)" refers to the annual change in eGFR. For example, in patients with chronic kidney disease, it can be identified by the slope of a straight line when GFR values ​​are measured over time and plotted on a graph with the vertical axis representing GFR (or eGFR) values ​​and the horizontal axis representing time. Generally, as chronic kidney disease progresses, GFR values ​​decrease linearly from the upper left to the lower right; a steeper slope of this line indicates a faster rate of decline in the glomerular filtration rate, or in other words, a faster rate of decline in kidney function. Thus, a steeper GFR slope (or eGFR slope) signifies a faster rate of decline in chronic kidney disease, which is associated with the exacerbation of the disease.

[0059] More specifically, the “rapid decrease in eGFR” as defined herein refers to a rapid decrease in the estimated glomerular filtration rate, which can be defined as an “eGFR slope <-5 ml / min / 1.73m2 / year.”

[0060] Hereinafter, with reference to FIGS. 2 to 7, an experimental example associated with a method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention will be described.

[0061] Specifically, Fig. 2 shows the Manhattan plot and Q-Q plot of the genome-wide association analysis for the rapid decline in eGFR in hypertensive patients from the Korean Chip Consortium (Discovery dataset), and Fig. 3 shows the genomic characteristics of rs183537972 in 7q31.32. Specifically, Fig. 3 (A) is a regional plot of the region surrounding rs183537972 in 7q31.32, where the red dots represent the most strongly linked read single nucleotide polymorphisms rs145083655 and rs183537972 (purple diamonds). Additionally, Fig. 3 (B) is the result of fine-mapping for rs183537972, showing the posterior probability of inclusion (PIP) plot of the fine-mapping around rs183537972 at + / - 100kb intervals. The single nucleotide polymorphisms around the blue circle in the plot are a reliable set with potential causal relationships, and s145083655 and rs183537972 were identified.

[0062] In addition, Figure 4 shows the association between serum creatinine concentrations between rs183537972 located near the HYAL6P gene and rs145083655 located in the HYAL4 gene using a linear regression model of genome-metabolite association analysis (GMIA), Figure 5 is a graph showing verified single nucleotide polymorphisms associated with a rapid decrease in eGFR based on genome-metabolite association analysis, Figure 6 is a graph showing the fine-mapping results of rs183537972 and rs145083655 in the HYAL6P and HYAL4 genes of chromosome 7q31.32, and Figure 7 is a graph showing the results of genome-metabolite association analysis for a rapid decrease in eGFR.

[0063] a) Research subjects

[0064] 1) Discovery genotyping dataset

[0065] The experiment described below, conducted in conjunction with our institution, was carried out as part of the project “Research on the Utilization of Genomic Information and Linkage with Public Data in Korean Genomic Epidemiology Data” under the Post-Genome Multi-Ministerial Genomics Project initiated in July 2020. This project involved obtaining epidemiological information from the Korean Chip-based community, urban, and rural cohorts, as well as omics big data (genomics, epigenetics, metabolomics), from the Korea National Institute of Health (NIH) under the Korea Disease Control and Prevention Agency (KDCA). This data is one of the largest cohort data sources representing the general Korean population. To obtain this data, a research plan and an application for exemption from review were submitted to the Institutional Review Board (IRB) of Seoul National University Hospital, and a notification of exemption was ultimately received. Based on this notification and the research plan, epidemiological information and omics big data based on the Korean Chip genomic information of a total of 72,298 individuals were distributed to the Human Resource Distribution Desk at the KDCA. The Korean chip genomic data was developed as a biobank array optimized for the Korean genome to address the shortcomings of existing commercial single polymorphism chips, which are designed primarily for Western populations and thus lack genomic representativeness for Asians. Since this data ensures the representativeness of the Korean genome by including Korean genetic mutation markers, it was actively utilized in experiments affiliated with our institution. Among the subjects with an eGFR slope of <-5 ml / min / 1.73m2 / year, only those with hypertension were included in the final study population.

[0066] 2) Validation: genotyping dataset

[0067] In addition, for this experiment, additional Korean subjects with chronic kidney disease were secured to perform external validation on the biomarkers discovered based on the Korean chip. A total of 2,306 samples from chronic kidney disease patients were collected, including 2,118 samples from the chronic kidney disease cohort (KoreaN cohort study for outcome in patients With Chronic Kidney Disease, KNOW-CKD) launched as an academic research project by the Korea Centers for Disease Control and Prevention in March 2011, and 188 samples from chronic kidney disease patients confirmed to have diabetic nephropathy by biopsy (91 samples from the Human Bioresource Bank at Seoul National University Hospital and 97 samples from Kyung Hee Medical Center). KNOW-CKD is a cohort for a multicenter prospective observational study involving a total of 2,388 adult patients aged 20 to 75 years, covering all stages of chronic kidney disease from stage 1 (diagnosed with stage 1) to stage 5 (predialysis). In the study affiliated with our hospital, blood samples were collected from 2,118 patients. A total of 2,045 samples passed quality control (QC) inspections. Of these, 273 patients with autosomal dominant polycystic kidney disease and 34 patients for whom the estimated glomerular filtration rate (eGFR) slope could not be calculated were excluded, resulting in a discovery cohort of 1,738 patients. Among the subjects with an eGFR slope <-5 ml / min / 1.73m2 / year in the data, only those with hypertension were included in the final study population. Consent forms and blood samples were obtained from all patients, and the study was approved by the Institutional Review Board of Seoul National University Hospital.

[0068] 3) Metabolite dataset

[0069] In this study, data on 135 serum metabolites measured from 2,580 participants in the community-based cohort of the Korean Genome Epidemiology Study (KoGES) were obtained. Of the 2,580 subjects, 1,905 participants overlapped with the Korean Chip Consortium and possessed both genotype and metabolite information.

[0070] b) Genotype Analysis and Quality Control

[0071] 1) Discovery dataset: Korean chips

[0072] The fabrication of the Korean Chip and the production of genomic information using the Korean Chip were carried out according to the following protocols, which are available from the Korean Chip Consortium. To maximize genomic representativeness for the Korean genome, a pilot chip was fabricated by selecting highly accurate genetic variants based on DNA sequences extracted from 2,576 Koreans. The final content was selected based on the results of analyzing the genomic information of 384 subjects. Genomic Coverage of over 95% (MAF) Single nucleotide polymorphisms of 5%) and over 73% (MAF 1–5%) were included, including functional variations, pharmacogenomic variations, eQTL variations affecting gene expression, and HLA region variations found in the Korean population. Ultimately, approximately 8,000,000 single nucleotide polymorphisms specific to the Korean population were included in the analysis.

[0073] 2) Validation dataset: KNOW-CKD

[0074] Whole blood samples from the study participants were collected in ethylenediaminetetraacetic acid tubes, and genomic DNA was extracted from peripheral blood leukocytes isolated therefrom. Genotype data was produced using the Korean Chip (Affymetrix Axiom KORV1.1, Santa Clara, CA, USA), developed by the National Institutes of Health Genome Center and provided by the K-CHIP Consortium. Quality control (QC) was performed using primary and secondary sample QC and SNP QC according to the Korean Chip protocol. Samples were excluded during primary sample QC based on the following criteria: (i) DQC (dish quality control) < 0.82, (ii) call rate < 97%, (iii) missing call rate ≥ 2%, (iv) heterozygosity outside the Mean ± 3SD range, (v) deviation from the pattern in the Multidimensional Deposition Scale (MDS) figure, and (vi) 15 or more singletones. Subsequently, a second sample QC was conducted with the following criteria: (i) DQC (dish quality control) < 0.82, (ii) call rate < 97%, (iii) missing call rate ≥ 2%, (iv) heterozygosity outside the mean ± 3SD, (v) deviation from the pattern in the MDS plot, (vi) 15 or more singletones, (vii) associated individuals (identical-bydescent > 0.8), and (viii) sex inconsistency. Subsequently, the following SNPs were excluded: (i) missing call rate ≥ 5%, and (ii) P-value (Hardy-Weinberg equilibrium test) < 10⁻⁶. As a result, 745,176 autosomal SNPs were identified, replaced with the reference panel of the 1000 Genomes Project phase 3 using Minimac3 and Shapeit_v2.Phase was adjusted using 12. Finally, after missing value imputation QC, 7,734,192 single nucleotide polymorphisms were used for analysis, excluding those with a coefficient of determination (R2) of less than 0.7 and multiple allele frequencies of less than 0.01.

[0075] 3) Metabolite dataset

[0076] A detailed protocol for the production of community-based cohort metabolite data is described in Yang et al., 2018. Briefly, serum metabolites were quantitatively analyzed using a targeted metabolite approach with the AbsoluteIDQ™ p180 kit (BIOCRATES Life Sciences, Innsbruck, Austria), which includes acylcarnitine, amino acids, biogenic amine phospholipids, hexoses, lipids, and glycerol. 10 μL of serum was aliquoted into a filtered 96-well plate and centrifuged at 100 xg for 2 minutes, analyzed by flow injection analysis / serial mass spectrometry (FIA-MS / MS), and quantified using liquid chromatography / tandem mass spectrometry (LC-MS / MS). The data quality of each metabolite is (1) a coefficient of variation <25% for each metabolite of the reference standard, (2) half the concentration of the metabolite analyzed in the reference standard > detection limit, and (3) half the concentration of the metabolite analyzed in the experimental sample > detection limit. Excluding 51 metabolites that did not pass the quality criteria, a final total of 135 metabolites (13 acylcarnitines, 21 amino acids, 10 bio-amines, 1 hexose, 78 glycerophospholipids, 12 sphingolipids) were included.

[0077] c) Statistical analysis

[0078] 1) GWAS Analysis

[0079] eGFR was calculated using the 4-variable CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula. In the Discovery dataset (Korean Inchip Consortium), only subjects with two or more follow-up points where eGFR was measured were selected, and the change in eGFR was calculated by dividing the change by the follow-up years. Meanwhile, in the validation dataset (KNOW-CKD cohort), the change in eGFR was calculated using a linear mixture model with a random intercept.

[0080] To explore genetic variations associated with the rapid decline in eGFR (eGFR slope <-5 ml / min / 1.73m2 / year) in hypertensive patients, an additive genetic model based on the Korean Chip Consortium was assumed using PLINK (version 2.0). GWAS analysis was performed on the rapid decline in eGFR (eGFR slope <-5 ml / min / 1.73m2 / year) using linear regression analysis. Among the derived single nucleotide polymorphisms, those with a P-value less than 1E-06 were considered to have a significant genomic association. To verify the significant association of single nucleotide polymorphisms found in the Korean Chip Consortium, data from the independent KNOW-CKD cohort were used; in the verification procedure, single nucleotide polymorphisms with a P-value less than 0.05 were considered verified. Manhattan plots and QQ (Quantile-Quantile) plots were created using R software version 4.1.0 (R Development Core Team; R Foundation for Statistical Computing, Vienna, Austria). Annotation for all single nucleotide polymorphisms was performed using the ANNOVAR and SNPnexus programs, and the beta and se values ​​of single nucleotide polymorphisms verified in discovery and validation studies were integrated through meta-analysis based on a fixed-effects model.

[0081] 2) Genome-metabolomics integrative analysis (GMIA)

[0082] GMIA was performed using a linear regression model to identify the metabolic mechanisms underlying genetic variation. The linear regression model was constructed between single nucleotide polymorphisms and serum concentrations. Pairs between single nucleotide polymorphisms and substitutes with a FDR (False Discover Rate) of less than 0.05, calculated through genome-metabolite analysis based on pre-calculated allele information from 135 metabolite data and the results of whole-genome association analysis based on an addictive model, were considered significant.

[0083] 3) Fine-mapping

[0084] Fine-mapping was performed to identify potential causal variants among single nucleotide polymorphisms in the GWAS using the Sum of Single Effects (SuSiE) method. Regions were selected within + / - 10kb around the read SNPs estimated to be the strongest association signals. Based on iterative Bayesian stepwise selection (IBSS), SuSiE regression models were estimated to calculate the Posterior Inclusion Probability (PIP), which is the probability that a single nucleotide polymorphism is included in a causal relationship, by isolating the effects of LD structures based on the 1000 Genome Project Phase 3 (East Asia) reference panel. A reliable set was generated through iterative model fitting, which is created by ranking single nucleotide polymorphisms from the largest PIP to the smallest PIP, and fine-mapping was performed using the "susieR" R package.

[0085] D) Result

[0086] 1) Single nucleotide polymorphisms significantly associated with a sharp decline in eGFR (eGFR slope <-5 ml / min / 1.73m2 / year)

[0087] In a discovery study based on the Korean Chip Consortium, the results of whole-genome association analysis conducted to identify single nucleotide polymorphisms associated with a rapid decrease in eGFR (eGFR slope <-5 ml / min / 1.73m2 / year) in a hypertensive patient group were presented as a Manhattan plot. As a result, 478 significant single nucleotide polymorphisms with a p-value of less than 10E-6 associated with a rapid decrease in eGFR were identified (see Figures 2 and 5).

[0088] 2) Validation results

[0089] In a validation study based on the KNOW-CKD cohort, a verification study of whole-genome association analysis was conducted, and 25 of the 478 single nucleotide polymorphisms derived from the discovery study were verified (based on a validation dataset p-value of 0.05).

[0090] 3) GMIA Results

[0091] Through GMIA, an increase in blood creatinine concentration was observed depending on the effector alleles (T and C) of rs145083655 and rs183537972 (see Figures 4 and 7).

[0092] 4) Fine-mapping results

[0093] As a result of zooming in on the regional plot and performing fine-mapping at 100kb intervals, two credible sets that could potentially be considered causal single nucleotide polymorphisms based on PIP were derived from the 7:123383533-123583533 region of the 7q31.32 cytoband. Both rs145083655 and rs183537972 were identified as credible sets and candidates for the causative variants with the highest PIP (see Figures 3 and 5).

[0094] Meanwhile, according to a study on the measurement of the socioeconomic burden of chronic kidney disease conducted in Korea, the socioeconomic cost of chronic kidney disease in 2011 is estimated to be approximately 5 trillion 219 billion won, including medical expenses, transportation costs, caregiving costs, time costs, loss of death, and loss of disability.

[0095] According to the present invention, by preventing chronic kidney disease in advance and proposing systematic treatment and management methods for individuals exposed to major risk factors for chronic kidney disease, it is possible to contribute to reducing the enormous socioeconomic costs associated with the disease. In other words, the multi-omics database based on the Korean chip and omics big data according to the present invention is expected to elevate the status of the medical industry and emerge as a high-profit business by realizing personalized medicine. Furthermore, since the present invention is a technology with significant potential for future application in various chronic diseases based on genomic analysis and multi-omics, technological advancements in the diagnostic field can foster specialized research personnel and are expected to contribute to solving the problem of youth unemployment in science and engineering fields.

[0096] Furthermore, according to the present invention, the progression of chronic kidney disease can be continuously monitored from before the onset of the disease to end-stage renal disease, thereby enabling intervention in advance regarding the natural history of the disease. Additionally, by utilizing multi-omics information (metabolites) to identify key genetic variations capable of disease intervention in chronic kidney disease, targets for preventive intervention can be proposed. This can serve as an opportunity to overcome the limitations of conventional epidemiological modeling and maximize overall data analysis capabilities by utilizing multi-omics technology.

[0097] Furthermore, this presents an opportunity to gain domestic and international recognition for the level of diagnostic and preventive technologies for chronic kidney disease. Given its high potential for application in actual patients, it is expected to serve as an important foundational technology closely linked to the pharmaceutical and healthcare industries. With the number of chronic kidney diseases increasing annually, it is anticipated that this will enable the reduction of socioeconomic burdens and the realization of personalized medicine by identifying mechanisms and causes based on multi-omics information.

[0098] For the first time in an Asian study, this invention identified a specific single nucleotide polymorphism having a significant correlation with a rapid decrease in estimated glomerular filtration rate (eGFR slope <-5 ml / min / 1.73m2 / year) in hypertensive patients, who are a high-risk group for chronic kidney disease, within the general Korean population; simultaneously, a verification procedure was conducted on the results of the said single nucleotide polymorphism in Korean patients with hypertensive chronic kidney disease.

[0099] Simultaneously, metabolites associated with the corresponding single nucleotide polymorphism were identified through integrated analysis with serum metabolites, and this specific single nucleotide polymorphism can be utilized as a biomarker to provide a molecular biological diagnostic technology for predicting the onset and prognosis of chronic kidney disease.

[0100] Single nucleotide polymorphism markers are easy to detect because they exist in DNA, are more stable than protein markers, and have the advantage of being easy to analyze as they occur at specific locations within chromosomes, while also being easily verifiable even in small amounts of blood samples rather than requiring tissue collection.

[0101] The present invention can provide a composition for predicting the occurrence and exacerbation of hypertensive chronic kidney disease in Koreans, comprising a preparation capable of detecting single nucleotide polymorphisms of rs145083655 and rs183537972 (NCBI refSNP ID), and a kit comprising the same. The present invention can not only identify single nucleotide polymorphisms rs145083655 and rs183537972 associated with the occurrence of chronic kidney disease in hypertensive patients of the general population, but also provide information for predicting exacerbation in patients with chronic kidney disease, and at the same time, provide information on related metabolites.

[0102] Accordingly, a kit capable of predicting the occurrence and exacerbation of hypertensive chronic kidney disease through the present invention, wherein the kit is an RT-PCR kit, a microarray chip, or a microfluidic chip. Detection of single nucleotide polymorphisms can be performed in various ways by sequencing, mini-sequencing, automated sequencing, TaqMan analysis, pyrosequencing, allele-specific PCR, dynamic allele-specific hybridization (DASH), PCR-RFLP (restriction fragment length polymorphism), PCR-SSCP (single strand conformation polymorphism), PCR-SSO (specific sequence oligonucleotide), hybridization by microarray, primer extension, Southern blot hybridization, dot hybridization, ASO (allele-specific oligonucleotide) hybridization combining PCR-SSO and dot hybridization, RCA (rolling circle amplification), HRM (high resolution melting), or MALDI-TOF / MS (matrix-assisted laser desorption ionization-time of flight mass spectrometry).

[0103] Below, based on the details described above, we will briefly examine the operation flow of the present invention.

[0104] FIG. 8 is a flowchart of the operation of a method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention.

[0105] The method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis illustrated in FIG. 8 can be performed by the analysis device (100) described above. Therefore, even if the details are omitted below, the description of the analysis device (100) can be applied equally to the description of FIG. 8.

[0106] Referring to FIG. 8, in step S11, the statistical analysis unit (120) can perform an association analysis between the allele scores for single nucleotide polymorphisms that are significantly related to the phenotype in the results of whole-genome association analysis and the metabolite concentration and allele information of the blood data included in the genomic information data collected and selected by the collection unit (110).

[0107] Next, in step S12, the diagnostic information generation unit (130) can estimate the slope of the subject's glomerular filtration rate based on the results of the association analysis.

[0108] Next, in step S13, the diagnostic information generation unit (130) can generate diagnostic information for the subject's hypertensive chronic kidney disease based on the estimated glomerular filtration rate gradient.

[0109] In the description above, steps S11 through S13 may be further divided into additional steps or combined into fewer steps according to an embodiment of the present invention. Additionally, some steps may be omitted as necessary, and the order between steps may be changed.

[0110] A method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis according to one embodiment of the present invention may be implemented in the form of program instructions that can be executed through various computer means and recorded on a computer-readable medium. The computer-readable medium may include program instructions, data files, data structures, etc., either individually or in combination. The program instructions recorded on the medium may be those specifically designed and configured for the present invention, or they may be those known and available to those skilled in the art of computer software. Examples of computer-readable recording media include magnetic media such as hard disks, floppy disks, and magnetic tapes; optical recording media such as CD-ROMs and DVDs; magneto-optical media such as floptical disks; and hardware devices specifically configured to store and execute program instructions, such as ROM, RAM, and flash memory. Examples of program instructions include machine code, such as that generated by a compiler, as well as high-level language code that can be executed by a computer using an interpreter, etc. The above-described hardware device may be configured to operate as one or more software modules to perform the operation of the present invention, and vice versa.

[0111] In addition, the aforementioned method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis can also be implemented in the form of a computer program or application executed by a computer stored on a recording medium.

[0112] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical concept or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single unit may be implemented in a distributed manner, and components described as distributed may likewise be implemented in a combined form.

[0113] The scope of the present invention is defined by the claims set forth below rather than by the detailed description above, and all modifications or variations derived from the meaning and scope of the claims and the concept of equivalents thereof should be interpreted as being included within the scope of the present invention. Explanation of the symbols

[0114] 100: Genome-Metabolite Integrated Analysis-Based Hypertensive Chronic Kidney Disease Analysis Device 110: Collection Department 120: Statistical Analysis Department 130: Diagnostic Information Generation Unit

Claims

Claim 1 A method for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis, performed by a device for analyzing hypertensive chronic kidney disease based on genome-metabolite integrated analysis, comprising: a step of collecting genomic information data of a plurality of subjects; a step of estimating the glomerular filtration rate gradient of each of the plurality of subjects based on the genomic information data and selecting genomic information data in which the estimated glomerular filtration rate gradient satisfies a preset gradient condition; a step of performing an association analysis between metabolite concentration and allele score based on a linear regression model linked to the metabolite concentration and allele information of blood data using the selected genomic information data; and a step of deriving analysis information on a single nucleotide polymorphism significantly associated with a phenotype linked to a target disease based on the results of the association analysis, wherein the target disease includes hypertensive chronic kidney disease and the single nucleotide polymorphism includes at least one of rs145083655 and rs183537972. Claim 2 delete Claim 3 The analysis method according to claim 1, wherein the screening step is to screen for genomic data of a subject whose estimated glomerular filtration rate slope decreases rapidly above a preset threshold slope. Claim 4 delete Claim 5 An analysis method according to claim 1, further comprising the step of generating diagnostic information regarding the target disease of the subject using the analysis information. Claim 6 In claim 5, the step of generating the diagnostic information is to derive the diagnostic information associated with the subject's hypertensive chronic kidney disease based on information regarding an increase in blood creatinine concentration according to an effective allele of a single nucleotide polymorphism comprising at least one of rs145083655 and rs183537972. Claim 7 An analysis device for hypertensive chronic kidney disease based on genome-metabolite integrated analysis comprises: a collection unit that collects genomic information data of a plurality of subjects, estimates the glomerular filtration rate gradient of each of the plurality of subjects based on the genomic information data, and selects genomic information data in which the estimated glomerular filtration rate gradient satisfies a preset gradient condition; and a statistical analysis unit that performs an association analysis between metabolite concentration and allele score based on a linear regression model linked to the metabolite concentration and allele information of blood data using the selected genomic information data, and derives analysis information regarding single nucleotide polymorphisms significantly associated with a phenotype linked to a target disease based on the results of the association analysis, wherein the target disease includes hypertensive chronic kidney disease, and the single nucleotide polymorphism includes at least one of rs145083655 and rs183537972. Claim 8 An analysis device according to claim 7, further comprising a diagnostic information generation unit that generates diagnostic information regarding the target disease of a subject using the analysis information. Claim 9 A composition for detecting a single nucleotide polymorphism (SNP) marker to predict the occurrence and exacerbation of hypertensive chronic kidney disease, wherein the single nucleotide polymorphism (SNP) marker is one or more selected from the group consisting of rs145083655 and rs183537972. Claim 10 A kit for diagnosing the prediction of occurrence and exacerbation of hypertensive chronic kidney disease using a single nucleotide polymorphism (SNP) marker, wherein the single nucleotide polymorphism (SNP) marker is one or more selected from the group consisting of rs145083655 and rs183537972.

Citation Information

Patent Citations

  • Marker for predicting exacerbation of chronic kidney disease and method for predicting exacerbation using the same

    KR102189144B1